We are live on
!
Find out more
DekaBank Deutsche Girozentrale Portfolio holdings
AUM
$59.2B
1-Year Est. Return
26.02%
This Fund
S&P 500
This Quarter
Est. Return
-11.33%
1 Year Est. Return
+26.02%
3 Year Est. Return
+92.08%
5 Year Est. Return
+125.09%
10 Year Est. Return
+457.34%
AUM
$15.1B
AUM Growth
-$1.81B
(-11%)
Cap. Flow
+$464M
Cap. Flow
% of AUM
3.07%
Top 10 Holdings %
Top 10 Hldgs %
22.68%
Holding
1,302
New
77
Increased
452
Reduced
571
Closed
126
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$835M |
| 2 |
Procter & Gamble
PG
|
+$87.9M |
| 3 |
Alibaba
BABA
|
+$50.4M |
| 4 |
Merck
MRK
|
+$47.1M |
| 5 |
Target
TGT
|
+$42.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$105M |
| 2 |
Texas Instruments
TXN
|
+$79.4M |
| 3 |
TSMC
TSM
|
+$77.5M |
| 4 |
Cisco
CSCO
|
+$55.8M |
| 5 |
NextEra Energy
NEE
|
+$47.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.2% |
| 2 | Healthcare | 16.02% |
| 3 | Financials | 13.93% |
| 4 | Communication Services | 9.97% |
| 5 | Consumer Discretionary | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Theravance Biopharma
TBPH
$876M
| $223K | ﹤0.01% |
9,600
-2,100
| -18% | -$56.7K |
|
|
GHDX
952
DELISTED
Genomic Health, Inc.
GHDX
| $223K | ﹤0.01% |
3,500
-3,300
| -49% | -$231K |
|
|
TLRD
953
DELISTED
Tailored Brands, Inc.
TLRD
| $222K | ﹤0.01% |
16,100
-1,600
| -9% | -$33K |
|
954
Vanda Pharmaceuticals
VNDA
$301M
| $220K | ﹤0.01% |
8,600
-2,000
| -19% | -$47K |
|
955
Garrett Motion
GTX
$5.52B
| $219K | ﹤0.01% |
+18,128
| New | +$246K |
|
956
Zillow
Z
$7.4B
| $219K | ﹤0.01% |
6,476
-1,752
| -21% | -$62.2K |
|
957
Zebra Technologies
ZBRA
$17.9B
| $217K | ﹤0.01% |
1,400
-3,352
| -71% | -$558K |
|
|
ADAP
958
DELISTED
Adaptimmune Therapeutics
ADAP
| $216K | ﹤0.01% |
44,500
+20,000
| +82% | +$148K |
|
959
Rayonier
RYN
$6.47B
| $212K | ﹤0.01% |
8,516
| – | – |
|
960
British American Tobacco
BTI
$123B
| $210K | ﹤0.01% |
6,679
| – | – |
|
961
Minerva Neurosciences
NERV
$201M
| $210K | ﹤0.01% |
+4,063
| New | +$297K |
|
962
Southern Copper
SCCO
$168B
| $205K | ﹤0.01% |
7,120
-12,728
| -64% | -$430K |
|
963
Eagle Bancorp
EGBN
$849M
| $203K | ﹤0.01% |
4,192
+500
| +14% | +$25.4K |
|
|
ALDR
964
DELISTED
Alder Biopharmaceuticals
ALDR
| $203K | ﹤0.01% |
19,800
-4,400
| -18% | -$56.3K |
|
965
NorthWestern Energy
NWE
$4.37B
| $201K | ﹤0.01% |
+3,394
| New | +$208K |
|
|
IMGN
966
DELISTED
Immunogen Inc
IMGN
| $201K | ﹤0.01% |
45,100
-10,000
| -18% | -$60.7K |
|
967
Intellia Therapeutics
NTLA
$1.7B
| $200K | ﹤0.01% |
16,300
-3,700
| -19% | -$68.8K |
|
968
Warrior Met Coal
HCC
$4.96B
| $198K | ﹤0.01% |
+8,308
| New | +$212K |
|
969
Grupo Aeroportuario del Pacifico
PAC
$12.9B
| $198K | ﹤0.01% |
2,368
| – | – |
|
|
BOLD
970
DELISTED
Audentes Therapeutics, Inc
BOLD
| $197K | ﹤0.01% |
9,400
-2,100
| -18% | -$54.2K |
|
|
LSXMA
971
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $194K | ﹤0.01% |
6,940
-34,729
| -83% | -$1M |
|
972
Fabrinet
FN
$19.4B
| $192K | ﹤0.01% |
+3,861
| New | +$185K |
|
|
WNS
973
DELISTED
WNS Holdings
WNS
| $191K | ﹤0.01% |
4,712
| – | – |
|
974
Novavax
NVAX
$1.29B
| $190K | ﹤0.01% |
5,055
-1,100
| -18% | -$42.6K |
|
975
SPS Commerce
SPSC
$2.65B
| $186K | ﹤0.01% |
+4,566
| New | +$199K |
|
Similar funds
QCM
NAMI
DekaBank Deutsche Girozentrale's Q4 2018 Portfolio in Review
As of Q4 2018, DekaBank Deutsche Girozentrale held 1,302 positions worth $15.1B, down 11% from $16.9B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
DekaBank Deutsche Girozentrale deployed $464M of net new capital in Q4 2018, opening 77 new positions and adding to 452 existing holdings. Its largest new stake was Linde: 5,283,074 shares worth $840M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $105M trimmed.
- DekaBank Deutsche Girozentrale's largest Q4 2018 buy was Linde: 5,283,074 shares worth $840M.
- DekaBank Deutsche Girozentrale added most to Procter & Gamble in Q4 2018, an estimated $87.9M increase.
- DekaBank Deutsche Girozentrale's biggest Q4 2018 reduction was Johnson & Johnson, cutting an estimated $105M.
- DekaBank Deutsche Girozentrale fully exited Express Scripts Holding Company in Q4 2018, selling an estimated $46.5M.
- DekaBank Deutsche Girozentrale's ten largest holdings make up 23% of its $15.1B portfolio in Q4 2018.
- DekaBank Deutsche Girozentrale opened 77 new positions and closed 126 in Q4 2018.
- DekaBank Deutsche Girozentrale's portfolio value fell 11% quarter-over-quarter to $15.1B.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2018, filed 12 Feb 2019.